PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21291529-0	2011	The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1alpha and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.	Epirubicin	213-223	vascular endothelial growth factor A	Homo sapiens	98-132	
20680681-4	2010	We investigated to compare the effects of the addition of tamoxifen to epirubicin versus epirubicin alone on VEGF and VEGFR2 expression in breast cancer patients.	Epirubicin	71-81	vascular endothelial growth factor A	Homo sapiens	109-113	
20680681-5	2010	The expression of VEGF and VEGFR2 was assessed on tissue microarray by immunohistochemistry at baseline conditions and after treatments in the case of 191 patients with T2-4 N0-1 breast cancer enrolled in a randomized trial comparing four cycles of single agent epirubicin versus epirubicin plus tamoxifen as primary systemic treatment.	Epirubicin	262-272	vascular endothelial growth factor A	Homo sapiens	18-22	
20680681-5	2010	The expression of VEGF and VEGFR2 was assessed on tissue microarray by immunohistochemistry at baseline conditions and after treatments in the case of 191 patients with T2-4 N0-1 breast cancer enrolled in a randomized trial comparing four cycles of single agent epirubicin versus epirubicin plus tamoxifen as primary systemic treatment.	Epirubicin	280-290	vascular endothelial growth factor A	Homo sapiens	18-22	
20680681-6	2010	Epirubicin alone failed to induce changes in VEGF expression (P = 0.54), while the addition of tamoxifen to epirubicin resulted in a significant reduction in VEGF expression (P < 0.001).	Epirubicin	108-118	vascular endothelial growth factor A	Homo sapiens	158-162	
20680681-7	2010	As a consequence, baseline VEGF had a negative prognostic role in patients who received epirubicin alone but not in patients receiving epirubicin plus tamoxifen (interaction test P < 0.05).	Epirubicin	88-98	vascular endothelial growth factor A	Homo sapiens	27-31	
12432274-6	2002	The results showed that epirubicin damaged tumor microvessels when the drug was given as a single dose, whereas epirubicin lost its vascular toxicity when the drug was given continuously for seven days, accompanied by higher levels of VEGF in tumor tissues.	Epirubicin	112-122	vascular endothelial growth factor A	Homo sapiens	235-239